Clinical Trials
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Vir Biotechnology, Inc. announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic...
Clinical Trials
New Clinical Research Accreditation Launches to Meet Industry Demands
GCSA launched with a commitment to increase clinical research and trial capacity and quality in the UK as well as Globally. This will be achieved...
Clinical Trials
Covid-19: Russia’s Sputnik V vaccine confirms 91.4% efficacy
Russia’s Sputnik V vaccine has demonstrated an efficacy of over 90 percent, according to the Gamaleya Center and the Russian Direct Investment Fund.
“Evaluation of efficacy...
Clinical Trials
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
Clinical Trials
Sanofi, GSK COVID-19 vaccine rollout delayed on low immune response in older adults
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim...
Clinical Trials
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment...
Clinical Trials
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Novartis announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.